ACTU
Actuate Therapeutics Inc.

94
Loading...
Loading...
News
all
press releases
News Placeholder
Actuate Therapeutics Stock Rises After Updating FDA Application For Lead Investigational Drug In Treating Pancreatic Cancer
Actuate on Monday also said that its recent $17.25 million public offering provides an extended runway into the second half of 2026.
Stocktwits·19d ago

Latest ACTU News

View

Advertisement|Remove ads.

Advertisement|Remove ads.